Informatie:
Fout:
ID
13809
Beschrijving
A Study Being Conducted at Multiple Locations to Compare the Safety and Effectiveness of Three Different Treatment Regimens; 1) Lenalidomide, 2) Lenalidomide + Azacitidine, or 3) Azacitidine Alone in Newly Diagnosed Acute Myeloid Leukemia in Elderly Subjects ≥ 65 Years of Age; ODM derived from: https://clinicaltrials.gov/show/NCT01358734
Link
https://clinicaltrials.gov/show/NCT01358734
Trefwoorden
Versies (1)
- 07-03-16 07-03-16 -
Houder van rechten
CC BY-NC 3.0
Geüploaded op
7 maart 2016
DOI
Voor een aanvraag inloggen.
Licentie
Creative Commons BY-NC 3.0
Model Commentaren :
Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.
Itemgroep Commentaren voor :
Item Commentaren voor :
U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.
Eligibility Acute Myeloid Leukemia NCT01358734
Eligibility Acute Myeloid Leukemia NCT01358734
- StudyEvent: Eligibility
Similar models
Eligibility Acute Myeloid Leukemia NCT01358734
- StudyEvent: Eligibility
Name
Type
Description | Question | Decode (Coded Value)
Datatype
Alias
AML de novo, with antecedent hematologic disorder or therapy-related
Item
newly diagnosed acute myeloid leukemia (aml), aml with antecedent hematologic disorder or therapy-related aml
boolean
C0023467 (UMLS CUI [1,1])
C1515568 (UMLS CUI [1,2])
C0018939 (UMLS CUI [2,1])
C0332152 (UMLS CUI [2,2])
C0023467 (UMLS CUI [3,1])
C2924519 (UMLS CUI [3,2])
C1515568 (UMLS CUI [1,2])
C0018939 (UMLS CUI [2,1])
C0332152 (UMLS CUI [2,2])
C0023467 (UMLS CUI [3,1])
C2924519 (UMLS CUI [3,2])
Age
Item
male or female subjects aged ≥ 65
boolean
C0001779 (UMLS CUI [1])
ECOG
Item
eastern cooperative oncology group (ecog) performance status of 0, 1 or 2
boolean
C1520224 (UMLS CUI [1])
WBC
Item
white blood cell (wbc) count ≤ 10 x 10⁹/l at screening
boolean
C0023508 (UMLS CUI [1])
previous treatment with azacitidine, decitabine, cytarabine or lenalidomide
Item
previous treatment with azacitidine, decitabine, cytarabine or lenalidomide
boolean
C1514463 (UMLS CUI [1])
C0004475 (UMLS CUI [2])
C0049065 (UMLS CUI [3])
C0010711 (UMLS CUI [4])
C1144149 (UMLS CUI [5])
C0004475 (UMLS CUI [2])
C0049065 (UMLS CUI [3])
C0010711 (UMLS CUI [4])
C1144149 (UMLS CUI [5])
prior therapy
Item
previous cytotoxic or biologic treatment of any kind for aml or prior use of targeted therapy agents.
boolean
C0304497 (UMLS CUI [1,1])
C1514463 (UMLS CUI [1,2])
C0005527 (UMLS CUI [2,1])
C1514463 (UMLS CUI [2,2])
C2985566 (UMLS CUI [3,1])
C1514463 (UMLS CUI [3,2])
C1514463 (UMLS CUI [1,2])
C0005527 (UMLS CUI [2,1])
C1514463 (UMLS CUI [2,2])
C2985566 (UMLS CUI [3,1])
C1514463 (UMLS CUI [3,2])
APL
Item
suspected or proven acute promyelocytic leukemia
boolean
C0023487 (UMLS CUI [1])
prior bone marrow or stem cell transplantation
Item
prior bone marrow or stem cell transplantation
boolean
C0005961 (UMLS CUI [1,1])
C0332152 (UMLS CUI [1,2])
C1504389 (UMLS CUI [2,1])
C0332152 (UMLS CUI [2,2])
C0332152 (UMLS CUI [1,2])
C1504389 (UMLS CUI [2,1])
C0332152 (UMLS CUI [2,2])
candidate for allogeneic bone marrow or stem cell transplantation
Item
candidate for allogeneic bone marrow or stem cell transplantation
boolean
C0005961 (UMLS CUI [1,1])
C1515895 (UMLS CUI [1,2])
C1504389 (UMLS CUI [2,1])
C1515895 (UMLS CUI [2,2])
C1515895 (UMLS CUI [1,2])
C1504389 (UMLS CUI [2,1])
C1515895 (UMLS CUI [2,2])
antecedent hematologic disorder
Item
aml antecedent hematologic disorder such as chronic myelogenous leukemia or myeloproliferative neoplasms
boolean
C0018939 (UMLS CUI [1,1])
C0332152 (UMLS CUI [1,2])
C0332152 (UMLS CUI [1,2])
malignant disease
Item
presence of malignant disease within the previous 12 months with exceptions
boolean
C0006826 (UMLS CUI [1,1])
C0040223 (UMLS CUI [1,2])
C0040223 (UMLS CUI [1,2])